Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action FX Vollenweider, MFI Vollenweider-Scherpenhuyzen, A Bäbler, H Vogel, ... Neuroreport 9 (17), 3897-3902, 1998 | 1073 | 1998 |
The neurobiology of psychedelic drugs: implications for the treatment of mood disorders FX Vollenweider, M Kometer Nature Reviews Neuroscience 11 (9), 642, 2010 | 813 | 2010 |
Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia D Umbricht, L Schmid, R Koller, FX Vollenweider, D Hell, DC Javitt Archives of general psychiatry 57 (12), 1139-1147, 2000 | 701 | 2000 |
Psychometric evaluation of the altered states of consciousness rating scale (OAV) E Studerus, A Gamma, FX Vollenweider PloS one 5 (8), e12412, 2010 | 618 | 2010 |
Psychological and cardiovascular effects and short-term sequelae of MDMA (“ecstasy”) in MDMA-naıve healthy volunteers FX Vollenweider, A Gamma, M Liechti, T Huber Neuropsychopharmacology 19 (4), 241-251, 1998 | 614 | 1998 |
Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies E Studerus, M Kometer, F Hasler, FX Vollenweider Journal of psychopharmacology 25 (11), 1434-1452, 2011 | 564 | 2011 |
Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose–effect study F Hasler, U Grimberg, MA Benz, T Huber, FX Vollenweider Psychopharmacology 172, 145-156, 2004 | 531 | 2004 |
Serotonin research: contributions to understanding psychoses MA Geyer, FX Vollenweider Trends in pharmacological sciences 29 (9), 445-453, 2008 | 526 | 2008 |
Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis FX Vollenweider, KL Leenders, C Scharfetter, P Maguire, O Stadelmann, ... Neuropsychopharmacology 16 (5), 357-372, 1997 | 520 | 1997 |
Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission … FX Vollenweider, KL Leenders, I Øye, D Hell, J Angst European Neuropsychopharmacology 7 (1), 25-38, 1997 | 468 | 1997 |
Acute effects of lysergic acid diethylamide in healthy subjects Y Schmid, F Enzler, P Gasser, E Grouzmann, KH Preller, FX Vollenweider, ... Biological psychiatry 78 (8), 544-553, 2015 | 463 | 2015 |
Gender differences in the subjective effects of MDMA ME Liechti, A Gamma, FX Vollenweider Psychopharmacology 154, 161-168, 2001 | 459 | 2001 |
Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F] fluorodeoxyglucose (FDG) FX Vollenweider, KL Leenders, C Scharfetter, A Antonini, P Maguire, ... European neuropsychopharmacology 7 (1), 9-24, 1997 | 436 | 1997 |
A systems model of altered consciousness: integrating natural and drug-induced psychoses FX Vollenweider, MA Geyer Brain research bulletin 56 (5), 495-507, 2001 | 421 | 2001 |
The fabric of meaning and subjective effects in LSD-induced states depend on serotonin 2A receptor activation KH Preller, M Herdener, T Pokorny, A Planzer, R Kraehenmann, ... Current Biology 27 (3), 451-457, 2017 | 390 | 2017 |
5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man—a PET study with [11C] raclopride FX Vollenweider, P Vontobel, D Hell, KL Leenders Neuropsychopharmacology 20 (5), 424-433, 1999 | 370 | 1999 |
Prediction of psilocybin response in healthy volunteers E Studerus, A Gamma, M Kometer, FX Vollenweider PloS one 7 (2), e30800, 2012 | 368 | 2012 |
Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders FX Vollenweider, KH Preller Nature Reviews Neuroscience 21 (11), 611-624, 2020 | 354 | 2020 |
Activation of serotonin 2A receptors underlies the psilocybin-induced effects on α oscillations, N170 visual-evoked potentials, and visual hallucinations M Kometer, A Schmidt, L Jäncke, FX Vollenweider Journal of Neuroscience 33 (25), 10544-10551, 2013 | 349 | 2013 |
Acute psychological effects of 3, 4-methylenedioxymethamphetamine (MDMA,“Ecstasy”) are attenuated by the serotonin uptake inhibitor citalopram ME Liechti, C Baumann, A Gamma, FX Vollenweider Neuropsychopharmacology 22 (5), 513-521, 2000 | 343 | 2000 |